ARTICLE | Clinical News
INX-3280: Phase I testing update
October 18, 1999 7:00 AM UTC
Inex Pharmaceuticals Corp. (TSE:IEX), Vancouver, B.C. Product: INX-3280 Business: Cancer Therapeutic category: Antisense Target: C-myc RNA Description: Antisense oligonucleotide against c-myc Indicat...